ANAB
Price
$24.69
Change
+$0.14 (+0.57%)
Updated
Aug 1 closing price
Capitalization
725.4M
9 days until earnings call
CLRB
Price
$4.72
Change
-$0.12 (-2.48%)
Updated
Aug 1 closing price
Capitalization
13.57M
16 days until earnings call
Interact to see
Advertisement

ANAB vs CLRB

Header iconANAB vs CLRB Comparison
Open Charts ANAB vs CLRBBanner chart's image
AnaptysBio
Price$24.69
Change+$0.14 (+0.57%)
Volume$326.87K
Capitalization725.4M
Cellectar Biosciences
Price$4.72
Change-$0.12 (-2.48%)
Volume$84.59K
Capitalization13.57M
ANAB vs CLRB Comparison Chart in %
Loading...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANAB vs. CLRB commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Hold and CLRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (ANAB: $24.69 vs. CLRB: $4.72)
Brand notoriety: ANAB and CLRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 56% vs. CLRB: 14%
Market capitalization -- ANAB: $725.4M vs. CLRB: $13.57M
ANAB [@Biotechnology] is valued at $725.4M. CLRB’s [@Biotechnology] market capitalization is $13.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 0 FA rating(s) are green whileCLRB’s FA Score has 0 green FA rating(s).

  • ANAB’s FA Score: 0 green, 5 red.
  • CLRB’s FA Score: 0 green, 5 red.
According to our system of comparison, ANAB is a better buy in the long-term than CLRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 5 TA indicator(s) are bullish while CLRB’s TA Score has 4 bullish TA indicator(s).

  • ANAB’s TA Score: 5 bullish, 4 bearish.
  • CLRB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ANAB is a better buy in the short-term than CLRB.

Price Growth

ANAB (@Biotechnology) experienced а -8.35% price change this week, while CLRB (@Biotechnology) price change was -7.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

ANAB is expected to report earnings on Nov 11, 2025.

CLRB is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANAB($725M) has a higher market cap than CLRB($13.6M). ANAB YTD gains are higher at: 86.480 vs. CLRB (-47.380). CLRB has higher annual earnings (EBITDA): -45.92M vs. ANAB (-76.35M). CLRB has less debt than ANAB: CLRB (474K) vs ANAB (15.6M). ANAB has higher revenues than CLRB: ANAB (112M) vs CLRB (0).
ANABCLRBANAB / CLRB
Capitalization725M13.6M5,331%
EBITDA-76.35M-45.92M166%
Gain YTD86.480-47.380-183%
P/E RatioN/AN/A-
Revenue112M0-
Total Cash340MN/A-
Total Debt15.6M474K3,291%
FUNDAMENTALS RATINGS
ANAB vs CLRB: Fundamental Ratings
ANAB
CLRB
OUTLOOK RATING
1..100
7473
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
91100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4665
P/E GROWTH RATING
1..100
7474
SEASONALITY SCORE
1..100
5015

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLRB's Valuation (56) in the Biotechnology industry is in the same range as ANAB (86). This means that CLRB’s stock grew similarly to ANAB’s over the last 12 months.

ANAB's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as CLRB (100). This means that ANAB’s stock grew similarly to CLRB’s over the last 12 months.

ANAB's SMR Rating (100) in the Biotechnology industry is in the same range as CLRB (100). This means that ANAB’s stock grew similarly to CLRB’s over the last 12 months.

ANAB's Price Growth Rating (46) in the Biotechnology industry is in the same range as CLRB (65). This means that ANAB’s stock grew similarly to CLRB’s over the last 12 months.

ANAB's P/E Growth Rating (74) in the Biotechnology industry is in the same range as CLRB (74). This means that ANAB’s stock grew similarly to CLRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABCLRB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ULPSX109.80N/A
N/A
ProFunds UltraBull Svc
PRCEX27.47N/A
N/A
Principal Real Estate Securities C
MUEVX39.33N/A
N/A
MFS Blended Research Core Equity R6
LSVFX11.07N/A
N/A
LSV Global Managed Volatility Instl
RPPRX30.18N/A
N/A
Victory RS Partners R6